Table 1.

Patient Demographics and Results of [¹¹C]MET and [¹¹C]PBR28 PET in SRS-Treated Patients.

Patient ID	Diagnosis	Tumor location	Sex	Age	Mutations	Months since SRS	Radiation dose (Gy)	Systemic therapy	Concurrent steroids	[11C]MET	[11C]PBR28	Pathology	Imaging follow-up (Months)
1	Melanoma	Right frontal	M	82	BRAF mutant	13.4	20	ArQule-736 (pan-RAF inhibitor); nivolumab	None	+	+	Tumor with RN
2	NSCLC	Right frontal	F	55	None	21.3	22	Cisplatin/etoposide	None	+	+	Tumor
3	Melanoma	Right frontal	M	56	BRAF wild-type	20.1	20	High dose IL-2; ipilimumab; pembrolizumab	None	–	–	RN
4	NSCLC	Left frontal	F	63	None	11.9	18	Carboplatin/pemetrexed	Yes	–	–	Presumed RN	8.5
		Right parietal				11.9	18			–	–	Presumed RN	8.5
5	NSCLC	Right frontal	M	62	KRAS mutant	8.3	18*	Carboplatin/paclitaxel	Yes	–	+	Presumed RN	12.5
		Left frontal				8.3	18*			–	+	RN

* Patient also had prior WBRT.